FDA fast-tracks RBI’s direct-to-brain stem cell treatment for Alzheimer’s (opens in new tab)

Regeneration Biomedical, Inc. (RBI) has been granted Fast Track designation by the U.S. Food and Drug Administration for its direct-to-brain, Wnt-activated autologous adipose-derived stem cell therapy for Alzheimer’s disease. The company completed a first-in-human Phase 1 study that it presented at the Clinical Trials on Alzheimer’s Disease meeting in 2025 and claims the trial showed […] The post appeared first on <a href="